Xenetic Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Xenetic Biosciences does not have a record of paying a dividend.

Key information

n/a

Dividend yield

n/a

Buyback Yield

Total Shareholder Yield	n/a
Future Dividend Yield	n/a
Dividend Growth	n/a
Next dividend pay date	n/a
Ex dividend date	n/a
Dividend per share	n/a
Payout ratio	n/a

Recent dividend and buyback updates

No updates

Recent updates

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Dec 15

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Dec 01

Xenetic Biosciences reports Q2 results

Aug 12

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Aug 02

Xenetic inks clinical manufacturing contract with Catalent

Jul 07

Xenetic Biosciences reports Q3 results

Nov 13

Stability and Growth of Payments

Fetching dividends data

Stable Dividend: Insufficient data to determine if XBIO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if XBIO's dividend payments have been increasing.

Dividend Yield vs Market

Xenetic Biosciences Dividend Yield vs Market

How does XBIO dividend yield compare to the market?
Segment	Dividend Yield
Company (XBIO)	n/a
Market Bottom 25% (US)	1.3%
Market Top 25% (US)	4.2%
Industry Average (Biotechs)	2.3%
Analyst forecast (XBIO) (up to 3 years)	n/a

Notable Dividend: Unable to evaluate XBIO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate XBIO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.

Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate XBIO's payout ratio to determine if its dividend payments are covered by earnings.

Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as XBIO has not reported any payouts.

Xenetic Biosciences Dividends and Buybacks

Dividend criteria checks 0/6

Key information

Recent dividend and buyback updates

Recent updates

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting Potential of Co-Administration of DNase I with CAR T Cells in Murine Model of Melanoma Lung Metastasis

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Xenetic Biosciences, Inc. Announces the Presentation of Positive Preclinical Data

Xenetic Biosciences, Inc., Annual General Meeting, Dec 11, 2024

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Xenetic Biosciences, Inc. Announces the Appointment of James Parslow as Interim Chief Executive Officer

First quarter 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

CLS Therapeutics Discloses its Views on Xenetic Biosciences

Xenetic Biosciences, Inc. Enters into Research Agreement with the University of Virginia for the Advancement of Its DNase-Based Oncology Platform

Xenetic Biosciences, Inc., Annual General Meeting, Dec 06, 2023

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Most Shareholders Will Probably Find That The Compensation For Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Is Reasonable

Xenetic Biosciences, Inc., Annual General Meeting, Dec 21, 2022

Xenetic Biosciences Receives a Non-Compliance Letter from Nasdaq

Why We Think Xenetic Biosciences, Inc.'s (NASDAQ:XBIO) CEO Compensation Is Not Excessive At All

Xenetic Biosciences, Inc. Announces the Appointment of Jonathan Spicer to its Scientific Advisory Board

Price target increased to US$4.00

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Xenetic Biosciences, Inc., Annual General Meeting, Dec 07, 2022

Xenetic Biosciences, Inc. announced that it expects to receive $0.488835 million in funding from CLS Therapeutics, Inc.

Xenetic Biosciences, Inc. Appoints Allan Tsung, to Its Scientific Advisory Board

Consensus forecasts updated

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences reports Q2 results

Xenetic Biosciences, VolitionRx collaborate to develop cell therapies to treat cancer

Xenetic inks clinical manufacturing contract with Catalent

Xenetic Biosciences Receives Written Notification from the Listing Qualifications Department of the Nasdaq

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Xenetic Biosciences, Inc. announced that it has received $0.86625 million in funding

High number of new directors

Third quarter 2021 earnings released: US$0.13 loss per share (vs US$1.20 loss in 3Q 2020)

Consensus EPS estimates increase to -US$0.55

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.15 loss in 2Q 2020)

Price target increased to US$5.00

Xenetic Biosciences, Inc. has completed a Follow-on Equity Offering in the amount of $6.000001 million.

Xenetic Biosciences reports Q3 results

Xenetic Biosciences Receives Notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC

Stability and Growth of Payments

Dividend Yield vs Market

Earnings Payout to Shareholders

Cash Payout to Shareholders

Discover strong dividend paying companies